1.24 USD
▼-0.09-6.77%
盘后 1.25 +0.71%
2026-11-20
市值
$12.64M
市盈率
—
EPS
-4.88
股息率
—
52 周区间
1.20 – 29.98
成交量
57.06K
Beta
0.56
目标价
17.00
52W 低 1.2052W 高 29.98
价格走势
公司简介
Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. It also develops SER-603, a LBP candidate optimized to treat disruptions in the GI...